ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,118Medicare Part D Prescriptions Filled, Including Refills

Rank: 103 out of 337

$403K Total Retail Price of All Prescriptions

Rank: 105 out of 337

384 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
20% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Rhode Island
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 384 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

15% of this provider’s 384 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

0% of this provider’s 6,630 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Rhode Island
PRAVASTATIN SODIUM 495 427 1 14
OMEPRAZOLE 464 348 2 4
HYDROCODONE-ACETAMINOPHEN 272 170 S3 3 13
ATENOLOL 251 201 4 10
CITALOPRAM HBR 232 175 5 17
FUROSEMIDE 217 184 6 8
ATORVASTATIN CALCIUM 213 197 7 7
LOSARTAN POTASSIUM 212 175 8 15
LEVOTHYROXINE SODIUM 210 187 9 5
LISINOPRIL 207 167 10 2
AMLODIPINE BESYLATE 184 176 11 3
METFORMIN HCL 174 114 12 12
METOPROLOL TARTRATE 170 144 13 6
FELODIPINE ER 148 141 14 79
WARFARIN SODIUM 146 132 15 11
TRAZODONE HCL 135 130 16 16
GABAPENTIN 116 65 17 20
SERTRALINE HCL 95 83 18 18
ZOLPIDEM TARTRATE 93 81 19 23
METOPROLOL SUCCINATE 89 89 20 21
BISOPROLOL-HYDROCHLOROTHIAZIDE 84 81 21 95
LISINOPRIL-HYDROCHLOROTHIAZIDE 83 75 22 31
SIMVASTATIN 83 76 22 1
SPIRIVA 79 59 24 43
COMBIVENT 77 33 25 126
ENALAPRIL MALEATE 74 64 26 37
ALLOPURINOL 70 67 27 28
HYDROCHLOROTHIAZIDE 69 69 28 9
LOSARTAN-HYDROCHLOROTHIAZIDE 65 65 29 60
DONEPEZIL HCL 62 62 30 22
OXYCONTIN 61 49 S2 31 87
KLOR-CON M20 61 51 31 65
ISOSORBIDE MONONITRATE ER 60 42 33 70
PREDNISONE 59 55 34 40
GLIPIZIDE ER 58 41 35 69
BUPROPION HCL SR 57 24 36 154
POLYETHYLENE GLYCOL 3350 55 38 37 47
FLUTICASONE PROPIONATE 54 26 38 34
ZETIA 53 53 39 89
LIPITOR 53 47 39 33
NITROFURANTOIN MONO-MACRO 52 50 41 197
RANITIDINE HCL 52 32 41 30
AZITHROMYCIN 51 44 43 51
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 15, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.